Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell common stock of the issuer. The filing lists proposed sales of 13,625 shares (option granted 02/13/2017) and 8,998 shares (option granted 02/12/2018), with an indicated date of 02/18/2026.
This notice reports proposed dispositions under issuer-granted options and indicates cash settlement; timing and expected proceeds are not stated in the excerpt.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell common stock of the issuer. The filing lists proposed sales of 13,625 shares (option granted 02/13/2017) and 8,998 shares (option granted 02/12/2018), with an indicated date of 02/18/2026.
This notice reports proposed dispositions under issuer-granted options and indicates cash settlement; timing and expected proceeds are not stated in the excerpt.
Johnson & Johnson insider plans Rule 144 stock sale. A holder has filed to sell 6,197 shares of Johnson & Johnson common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,508,299.61 and 2,409,898,936 shares reported outstanding.
The shares to be sold were acquired as compensation through restricted stock vesting from the issuer on several dates in 2025 and 2026, including 5,110 shares vesting on February 13, 2026. The seller represents they are not aware of undisclosed material adverse information about the company.
Shareholder James Swanson filed a Rule 144 notice to sell 20,521 Johnson & Johnson common shares with an aggregate market value of $4,980,510.40. The shares are planned to be sold on the NYSE around 02/17/2026 through Fidelity Brokerage Services LLC.
These shares were acquired on 02/17/2026 via options granted on 02/08/2021, with the 20,521 shares paid for in cash. Over the prior three months, Swanson sold 41,559 Johnson & Johnson common shares on 02/13/2026 for gross proceeds of $10,129,245.92.
An affiliate of the issuer filed a notice to sell 89,654 shares of common stock under Rule 144. The shares are planned to be sold on the NYSE through Fidelity Brokerage Services LLC with an aggregate market value of $21,767,964.99 as stated in the filing.
The securities were recently acquired through restricted stock vesting and stock option exercises between 02/13/2026 and 02/17/2026, with consideration described as compensation or cash. Shares outstanding were 2,409,898,936 as of the data provided, which serves as a baseline figure.
A holder of Johnson & Johnson common stock filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 53,931 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of 13105233.00, around 02/17/2026.
The securities to be sold were recently acquired from the issuer via restricted stock vesting of 2,283 shares on 02/15/2026 and option exercises totaling 51,648 shares on 02/17/2026. Johnson & Johnson had 2,409,898,936 common shares outstanding at the time referenced.
Johnson & Johnson filed a Form 13F holdings report disclosing its reported institutional holdings. The report lists 17 information-table entries with a total value of $554,625,589. The filing names Johnson & Johnson Innovation - JJDC, Inc. as an included manager and was signed by Marc Larkins on 02-13-2026.
A holder of common stock has filed a notice under Rule 144 to sell 41,559 shares through Fidelity Brokerage Services LLC on or about 02/13/2026 on the NYSE. The filing lists an aggregate market value of 10129245.92 for this planned sale.
The shares relate to option grants from 02/14/2022 and 02/13/2023, with 19,368 and 22,191 shares respectively acquired for cash on 02/13/2026. Common shares outstanding were 2409898936 as of the information provided.
Johnson & Johnson executive Joseph J. Wolk, Exec VP and CFO, was granted 37,463 Performance Share Units on February 9, 2026. These PSUs were awarded under the company’s Long-Term Incentive Plan tied to a grant originally made on February 13, 2023.
The PSUs convert into shares of common stock upon vesting. The 37,463 units reflect the target award adjusted based on achievement of performance conditions in the award agreement, which were certified on February 9, 2026. Following this transaction, Wolk directly holds 37,463 derivative securities.
Johnson & Johnson executive Jennifer Taubert reported an equity award tied to performance. On February 9, 2026, she acquired 27,412 Performance Share Units (PSUs) at a price of $0. These PSUs were originally granted on February 13, 2023 under the company’s Long-Term Incentive Plan.
The 27,412 PSUs represent the target award adjusted based on achievement of performance conditions, which were certified on February 9, 2026. The PSUs convert into shares of Johnson & Johnson common stock upon vesting, so their ultimate value depends on both vesting and the company’s share price at that time.
Johnson & Johnson executive James D. Swanson, EVP and CIO, reported an equity award tied to prior performance. On February 9, 2026, he acquired 9,412 Performance Share Units at a price of $0.00 per unit. These PSUs were originally granted under the company’s Long-Term Incentive Plan on February 13, 2023 and convert into shares of common stock upon vesting.
The 9,412-unit amount reflects the target PSUs from the 2023 grant, adjusted based on achievement of the performance conditions specified in the award agreement, which were certified on February 9, 2026. Following this transaction, Swanson directly holds 9,412 derivative securities in the form of these PSUs.